ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/gastric-and-oesophageal/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Gastric and oesophageal - Advanced/metastatic
36
trial(s) found.
NCT06921837
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer (
BBI-4182-101
)
anti-CLDN18.2 immune-stimulating antibody conjugate,TLR7/8 agonist
Adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06617169
Advanced
Phase 1
Recruiting
Open Label, Phase 1a, Dose-Escalation Study Evaluating the Safety of Fractionated MNPR-101-PCTA-177Lu Dosing in the Treatment of Solid Tumor Cancers (
MNPR101-Lu-1-01
)
177Lu-anti-uPAR radioconjugate
Bladder cancer
Colorectal cancer
Gastric cancer
Lung cancer
Ovarian cancer
Pancreatic cancer
Solid tumour
Triple-negative breast cancer
Urothelial carcinoma
VIC
3051 - North Melbourne - Melbourne Theranostic Innovation Centre
NCT06585488
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplifications (
BGB-53038-101
)
pan-KRAS inhibitor
Cancer
Colorectal cancer
Gastric cancer
Non-squamous non-small-cell lung cancer
Oesophageal adenocarcinoma
Pancreatic adenocarcinoma
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Breast cancer
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Urothelial carcinoma
Uterine serous carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06427941
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors (
BGB-B2033-101
)
anti-GPC3 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Hepatocellular carcinoma
Solid tumour
Squamous non-small-cell lung cancer
Yolk sac tumour
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06257264
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors (
BG-68501-101
)
CDK2 inhibitor
Bladder cancer
Breast cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Ovarian cancer
Prostate cancer
Small-cell lung cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06238479
Advanced
Phase 1
Recruiting
A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors (
EXCEED
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
Biliary tract cancer
Cancer
Gastric cancer
Pancreatic adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06157892
Advanced
Phase 2
Recruiting
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors (
SGNDV-004
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-low breast cancer
HER2-positive breast cancer
Triple-negative breast cancer
VIC
3199 - Frankston - Peninsula Health Frankston Hospital
NA
NA
NCT06116136
Advanced
Phase 1 / Phase 2
Recruiting
Open Label, Non-randomized, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of S095029 (Anti-NKG2A Antibody) as a Part of Combination Therapy in Participants With Locally Advanced and Unresectable or Metastatic MSI-H/dMMR Gastro-esophageal Junction /Gastric Cancer (
CL1-95029-002
)
anti-NKG2A monoclona antibody
Cancer
Gastric cancer
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05891171
Advanced
Phase 1
Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (
ARC-25
)
anti-CD39 monoclonal antibody
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Triple-negative breast cancer
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT05581004
Advanced
Phase 1
Recruiting
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (
GO43860
)
unknown drug class
Gastric cancer
Head and neck squamous cell carcinoma
Melanoma
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05411133
Advanced
Phase 1
Recruiting
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies (
A001
)
bispecific T-cell engager,CDH17-targeting
Cholangiocarcinoma
Colorectal adenocarcinoma
Gastric cancer
Gastrointestinal cancer
Hepatocellular carcinoma
Oesophageal adenocarcinoma
Pancreatic cancer
NSW
2217 - Kogarah - St George Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05094336
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors (
MTAPESTRY-101
)
PRMT5 inhibitor
taxane
Gastric cancer
Gastroesophageal cancer
Pancreatic adenocarcinoma
Squamous non-small-cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3002 - East Melbourne - Epworth Freemasons
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT05002127
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Study of Evorpacept (ALX148) in Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06) (
AT148006
)
CD47-blocking fusion protein
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - ICON Cancer Care
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
taxane
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04644068
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (
PETRA
)
PARP1-selective inhibitor
Biliary tract cancer
Bladder cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Small-cell lung cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT04140526
Advanced
Phase 1 / Phase 2
Recruiting
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (
PRESERVE-001
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenoid cystic carcinoma
Breast cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Salivary gland cancer
Sarcoma
Small-cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2305 - New Lambton Heights - Newcastle Private Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
NSW
2640 - Albury - Albury Wodonga Regional Cancer Centre
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06465069
Advanced
Phase 1
Suspended
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (
NEXUS-01
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06341647
Advanced
Phase 1
Withdrawn
A Multicenter, Open-label, Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced Human Epidermal Growth Factor Receptor 2 Positive(HER2+) Solid Tumors (
HREC-233-23
)
allogeneic CAR-NK-cell therapy,ERBB2-targeting
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
NCT05867121
Advanced
Phase 1
Active not recruiting
A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors (
GO44010
)
anti-TGF-beta monoclonal antibody
Gastric cancer
Non-small cell lung cancer
Pancreatic adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05858736
Advanced
Phase 1
Active not recruiting
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study (
PRESERVE-009
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenocarcinoma
Anal cancer
Biliary tract cancer
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Fallopian tube cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Primary peritoneal serous carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05605522
Advanced
Phase 1
Active not recruiting
A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours (
FPI-2059-101
)
radioconjugate,NTSR1-targeting
Colorectal cancer
Ewing sarcoma
Gastric cancer
Head and neck squamous cell carcinoma
Pancreatic adenocarcinoma
Prostate cancer
Solid tumour
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
NCT05500508
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer (
AMXT1501-102
)
polyamine transport inhibitor
Breast cancer
Cancer
Central nervous system cancer
Cervical cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
H3K27M-mutant glioma
Head and neck cancer
Malignant glioma
Melanoma
Mesothelioma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Papillary thyroid cancer
Pleural mesothelioma
Solid tumour
NSW
2145 - Westmead - The Children's Hospital at Westmead
NCT05363605
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours (
FPI-1966-101
)
radioconjugate,FGFR3-targeting
Bladder cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Lung cancer
Ovarian cancer
Solid tumour
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05311176
Advanced
Phase 2
Terminated
nextHERIZON
: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment
ERBB2 B-cell antigen
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2500 - Wollongong - Wollongong Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
NCT03900442
Advanced
Phase 1
Unknown status
Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies (
PTX-100-PD-012017
)
geranylgeranyl transferase inhibitor
Colorectal cancer
Gastric cancer
Multiple myeloma
Pancreatic adenocarcinoma
Peripheral T-cell lymphoma
VIC
3002 - East Melbourne - Epworth Freemasons
NCT02773524
Advanced
Phase 3
Unknown
A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) (
INTEGRATEIIa
)
KIT/PDGFR/RET/VEGFR/FGFR inhibitor
placebo
Gastroesophageal cancer
NT
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Prince of Wales Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2485 - Tweed Heads - The Tweed Hospital
2640 - Albury - Border Medical Oncology Research Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (25)
Active not recruiting (3)
Terminated (3)
Not yet recruiting (1)
Suspended (1)
Withdrawn (1)
Unknown status (1)
Unknown (1)
Recruitment Country and State
NSW (24)
VIC (21)
SA (12)
QLD (11)
WA (11)
NZ (5)
TAS (2)
ACT (1)
NT (1)
Phase
Phase 1 (18)
Phase 1 / Phase 2 (9)
Phase 2 (6)
Phase 2 / Phase 3 (1)
Phase 3 (2)
Trial Type
Advanced (36)
Cancer Therapy Class
PD-1
33%
PD-1/PD-L1
33%
ERBB2
22%
CLDN18.2
6%
ER
6%
oestrogen axis
6%
NECTIN4
6%
MET
6%
PD-L1
6%
VEGFR2
6%
CTLA4
6%
FGFR
6%
FGFR3
6%
TIGIT
3%
EGFR
3%
KRAS
3%
GPC3
3%
CDK2
3%
CDK4
3%
CDK4 selective
3%
B7H3
3%
ERBB3
3%
CD39
3%
CDH17
3%
PRMT5
3%
IL-2
3%
CD47
3%
CCR8
3%
PARP
3%
PARP1-selective
3%
Trop2
3%
DPD
3%
TGF-beta
3%
orotate phosphoribosyltransferase
3%
NTSR1
3%
polyamine transport
3%
geranylgeranyl transferase
3%
FGFR1
3%
FGFR1/2/3
3%
FGFR2
3%
FGFR4
3%
KIT
3%
PDGFR
3%
RET
3%
VEGFR
3%
Facility
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (8)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
3168 - Clayton - Monash Medical Centre (6)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
6009 - Nedlands - Linear Clinical Research (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
5011 - Woodville South - The Queen Elizabeth Hospital (4)
6150 - Murdoch - Fiona Stanley Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
2109 - North Ryde - Macquarie University Hospital (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
5042 - Bedford Park - Flinders Medical Centre (3)
4575 - Birtinya - Sunshine Coast University Hospital (2)
3004 - Melbourne, Southbank - Alfred Health (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (2)
2031 - Randwick - Prince of Wales Hospital (2)
2139 - Concord - Concord Repatriation General Hospital (2)
3002 - East Melbourne - Epworth Freemasons (2)
2305 - New Lambton Heights - Newcastle Private Hospital (2)
4215 - Southport - Tasman Oncology (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
3051 - North Melbourne - Melbourne Theranostic Innovation Centre (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
NA
2217 - Kogarah - St George Private Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
4120 - Greenslopes - Greenslopes Private Hospital- Gallipoli Medical Research Foundation (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
4215 - Southport - ICON Cancer Care (1)
2170 - Liverpool - Liverpool Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
6009 - Nedlands - One Clinical Research (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2500 - Wollongong - Wollongong Hospital (1)
0810 - Tiwi, Royal Darwin Hospital - Northern Centre for Oncology (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2217 - Kogarah - St George Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2485 - Tweed Heads - The Tweed Hospital (1)
2605 - Garran - The Canberra Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
5035 - Ashford - Flinders Medical Centre, Ashford Cancer Centre Research (1)
7000 - Hobart - Royal Hobart Hospital (1)
Cancer Type
Cancer
Gastroesophageal cancer
Gastrointestinal cancer
Solid tumour
Upper gastrointestinal cancer
Gastric cancer
Thoracic cancer
Oesophageal cancer
Lung cancer
Respiratory tract cancer
Pancreatobiliary cancer
Pancreatic cancer
Urogenital cancer
Breast cancer
Gynaecological cancer
Non-small cell lung cancer
Colorectal cancer
Head and neck cancer
Lower gastrointestinal cancer
Ovarian cancer
Cervical cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Bladder cancer
Head and neck squamous cell carcinoma
Male genital cancers
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Hepatobiliary cancer
Melanoma
Prostate cancer
Breast adenocarcinoma
Triple-negative breast cancer
Kidney cancer
Endometrial cancer
Clear cell renal cell carcinoma
Hepatocellular carcinoma
Carcinoma
Biliary tract cancer
Sarcoma
Urothelial carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Gastric adenocarcinoma
Squamous non-small-cell lung cancer
Colorectal adenocarcinoma
Adenocarcinoma
Non-squamous non-small-cell lung cancer
Oesophageal adenocarcinoma
Endometrial carcinoma
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Prostate adenocarcinoma
Renal pelvis cancer
Fallopian tube cancer
Mesothelioma
Peritoneal cancer
Pleural mesothelioma
Primary peritoneal serous carcinoma
Central nervous system cancer
Endocrine gland cancer
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Thyroid cancer
HER2-positive gastric cancer
Uterine serous carcinoma
Germ cell tumour
Non-seminoma
Testicular cancer
Yolk sac tumour
Castrate-resistant prostate cancer
Platinum resistant ovarian cancer
HER2-low breast cancer
HER2-negative breast cancer
HER2-positive breast cancer
Oesophageal squamous cell carcinoma
Cholangiocarcinoma
Acral lentiginous melanoma
Biomarker-defined solid tumour
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
MSI-H/dMMR solid tumour
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Skin cancer
dMMR solid cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Adenoid cystic carcinoma
Cancer Solid tumour Carcinoma
Salivary gland cancer
Colon adenocarcinoma
Glioblastoma
MET:alteration
MET:fusion
Anal cancer
Bone cancer
Ewing family of tumours
Ewing sarcoma
Primitive neuroectodermal tumour
Differentiated thyroid carcinoma
H3K27M-mutant glioma
Papillary thyroid cancer
Haematological malignancy
Lymphoma
Multiple myeloma
Non-Hodgkin's lymphoma
Peripheral T-cell lymphoma
Plasma cell disorder
T-cell lymphoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy